Dose-Dense Docetaxel and Radium-223 in Bone-Dominant Metastatic Castration-Resistant Prostate Cancer

• Published in: Clinical genitourinary cancer Vol. 23; no. 4; p. 102368
• Main Authors: Connell, Brendan, Hwang, Clara, Folefac, Edmund, Lawlor, Christian, Koethe, Benjamin, Mathew, Paul
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2025
• Subjects: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bone metastases; Bone Neoplasms - drug therapy; Bone Neoplasms - secondary; Bone Neoplasms - therapy; Combination therapy; Docetaxel - administration & dosage; Docetaxel - adverse effects; Dose-Response Relationship, Drug; Efficacy; Granulocyte Colony-Stimulating Factor - administration & dosage; Humans; Lead-in cycle; Male; Maximum Tolerated Dose; Middle Aged; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - pathology; Prostatic Neoplasms, Castration-Resistant - therapy; Radium - administration & dosage; Radium - adverse effects; Safety; Treatment Outcome; Efficacy; Safety; Combination therapy; Bone metastases; Lead-in cycle

Disease progression in castration-resistant prostate cancer (CRPC) remains bone-dominant and docetaxel-responsive. Docetaxel and radium-223 would be a logical combination but myelosuppression is dose-limiting. Dose-dense schedules of docetaxel have comparable activity to bolus dosing with mitigated...